Publications by authors named "R Vij"
We present a study of rare germline predisposition variants in 954 unrelated individuals with multiple myeloma (MM) and 82 MM families. Using a candidate gene approach, we identified such variants across all age groups in 9.1% of sporadic and 18% of familial cases.
View Article and Find Full Text PDFBackground: This analysis explored real-world characteristics, treatment patterns and clinical outcomes in patients with relapsed or refractory multiple myeloma (RRMM) previously treated with lenalidomide and an anti-CD38 monoclonal antibody (mAb) and requiring subsequent treatment.
Materials And Methods: The PREAMBLE and Connect MM prospective registries of patients with multiple myeloma (MM), and the US nationwide Flatiron Health electronic health record-derived de-identified database were analysed. MM-specific treatment patterns (prior/index therapies) and outcomes (progression-free survival [PFS]/overall survival [OS]) were assessed.
Surface-enhanced Raman spectroscopy (SERS) is a powerful tool for biomolecule sensing. When combined with a broadband plasmonic structure, label-free, highly sensitive detection of specific molecules is possible. It is non-invasive, sensitive, fast, and can be used for in-situ analysis, unlike enzyme-linked immunosorbent assay, fluorescence immunoassay, and radioimmunoassay.
View Article and Find Full Text PDFArticle Synopsis
- Multiple Myeloma (MM) is an incurable cancer affecting plasma cells, with over 35,000 new cases diagnosed each year in the U.S., leading to frequent relapses and limited treatment options.
- Researchers used transcriptome sequencing to compare newly diagnosed MM patients with short progression-free survival (PFS) to those with longer PFS, identifying 157 lncRNAs associated with poor outcomes, particularly focusing on one specific lncRNA.
- The study found that the overexpression of this lncRNA enhances cell viability and decreases apoptosis, while its knockdown has the opposite effect, and targeted therapies using antisense oligonucleotides showed potential in reducing cell viability and promoting apoptosis in MM cells.
Objective: This intermediate-size expanded access program aimed to evaluate safety and clinical efficacy of multiple intravenous infusions of autologous, Hope Biosciences adipose-derived mesenchymal stem cell (HB-adMSC) therapy in elderly patients with Parkinson's disease (PD).
Methods: Ten eligible participants (aged 76-95 years) received six intravenous infusions each with 200MM autologous HB-adMSCs over 18 weeks, with the end of study (EOS) at week 26. Safety was assessed through adverse events (AEs) and serious adverse events (SAEs).